The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Skytrofa (previously Lonapegsomatropin Ascendis Pharma) lonapegsomatropin Orphan | Ascendis Pharma Endocrinology Division A/S | Growth and Development | 🇪🇺 EU 2022-01-11 | Order → |
| Tavneos avacopan PRIMEAdditional monitoring | Vifor Fresenius Medical Care Renal Pharma France | Microscopic Polyangiitis; Wegener Granulomatosis | 🇪🇺 EU 2022-01-11 | Order → |
| Voraxaze glucarpidase OrphanExceptional circumstancesAdditional monitoring | SERB SAS | Metabolic Side Effects of Drugs and Substances | 🇪🇺 EU 2022-01-11 | Order → |
| Lumykras sotorasib ConditionalAdditional monitoring | Amgen Europe B.V. | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2022-01-06 | Order → |
| Riltrava Aerosphere formoterol fumarate dihydrate;glycopyrronium;budesonide | AstraZeneca AB | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2022-01-06 | Order → |
| Tecovirimat SIGA tecovirimat monohydrate Exceptional circumstancesAdditional monitoring | SIGA Technologies Netherlands B.V. | Poxviridae Infections; Cowpox; Monkeypox; Vaccinia; Smallpox | 🇪🇺 EU 2022-01-06 | Order → |
| Wegovy semaglutide | Novo Nordisk A/S | Obesity; Overweight | 🇪🇺 EU 2022-01-06 | Order → |
| Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) Additional monitoring | Sanofi Winthrop Industrie | COVID-19 virus infection | 🇪🇺 EU 2021-12-20 | Order → |
| Xevudy sotrovimab Additional monitoring | GlaxoSmithKline Trading Services Limited | COVID-19 virus infection | 🇪🇺 EU 2021-12-17 | Order → |
| Aspaveli pegcetacoplan Orphan | Swedish Orphan Biovitrum AB (publ) | Hemoglobinuria, Paroxysmal | 🇪🇺 EU 2021-12-13 | Order → |
| Vaxneuvance pneumococcal polysaccharide conjugate vaccine (adsorbed) | Merck Sharp & Dohme B.V. | Pneumococcal Infections | 🇪🇺 EU 2021-12-13 | Order → |
| Cibinqo abrocitinib | Pfizer Europe MA EEIG | Dermatitis, Atopic | 🇪🇺 EU 2021-12-09 | Order → |
| Rybrevant amivantamab Additional monitoring | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2021-12-09 | Order → | |
| Sitagliptin SUN sitagliptin fumarate Generic | Sun Pharmaceutical Industries Europe B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2021-12-09 | Order → |
| Artesunate Amivas artesunate OrphanAdditional monitoring | Amivas Ireland Ltd | Malaria | 🇪🇺 EU 2021-11-22 | Order → |
| Brukinsa zanubrutinib Additional monitoring | BeOne Medicines Netherlands B. V. | Waldenstrom Macroglobulinemia | 🇪🇺 EU 2021-11-22 | Order → |
| Trodelvy sacituzumab govitecan Additional monitoring | Gilead Sciences Ireland UC | Breast Neoplasms; Triple Negative Breast Neoplasms | 🇪🇺 EU 2021-11-22 | Order → |
| Gavreto pralsetinib ConditionalAdditional monitoring | Blueprint Medicines (Netherlands) B.V. | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2021-11-18 | Order → |
| Qinlock ripretinib Orphan | Deciphera Pharmaceuticals (Netherlands) B.V. | Gastrointestinal Stromal Tumors | 🇪🇺 EU 2021-11-18 | Order → |
| Hukyndra adalimumab Biosimilar | Stada Arzneimittel AG | Arthritis, Psoriatic; Arthritis, Juvenile Rheumatoid; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Hidradenitis Suppurativa; Psoriasis; Spondyliti | 🇪🇺 EU 2021-11-15 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.